Cannell & Spears’s DexCom DXCM Stock Holding History

Cannell & Spears’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,152	Closed	-$222K	–	240
2020 Q3	$222K	Hold	2,152	–	–	0.02%	207
2020 Q2	$218K	Buy	+2,152	New	+$193K	0.02%	201

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cannell & Spears's DXCM Position: Q4 2020 in Review

Cannell & Spears sold out of DexCom (DXCM) in Q4 2020, closing a stake of 2,152 shares — an estimated $222K sold.

Cannell & Spears first reported a position in DXCM in Q2 2020 and held it in 2 quarters. The position peaked at $222K in Q3 2020. 732 funds tracked by Wall St. Rank hold DXCM as of Q4 2020.

Cannell & Spears reported no remaining DexCom position as of Q4 2020 after selling out during the quarter.
Cannell & Spears sold 2,152 DexCom shares in Q4 2020, an estimated $222K.
Cannell & Spears first reported a position in DexCom in Q2 2020 and held it in 2 quarters.
Cannell & Spears's DexCom position peaked at $222K in Q3 2020.
732 funds tracked by Wall St. Rank held DexCom as of Q4 2020.

Based on Cannell & Spears's 13F filing for Q4 2020, filed 12 Feb 2021.